Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.34% | 56.91% | 42.69% | 42.30% | 57.61% |
| Total Depreciation and Amortization | -54.92% | -43.81% | -38.89% | -37.90% | -38.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,208.27% | -157.40% | -113.77% | -100.13% | -97.20% |
| Change in Net Operating Assets | 100.98% | 68.52% | 101.58% | 91.69% | -46.28% |
| Cash from Operations | 6.21% | 8.77% | 13.13% | 28.39% | 29.50% |
| Capital Expenditure | -122.92% | -69.71% | -9.30% | 52.41% | 69.10% |
| Sale of Property, Plant, and Equipment | 5,151.89% | 5,151.89% | -100.00% | -90.57% | -90.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.45% | -43.49% | -32.18% | -46.70% | -55.61% |
| Cash from Investing | 41.26% | 2.15% | -38.51% | -49.33% | -57.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 269.70% | 293.33% | -61.16% | -71.90% | -94.21% |
| Repurchase of Common Stock | 0.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -93.33% | -- | -- | -- | -- |
| Cash from Financing | -99.71% | 140,293.33% | 34,649.59% | 34,638.84% | 7,274.21% |
| Foreign Exchange rate Adjustments | -66.67% | -106.45% | -126.61% | -12.50% | 103.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.57% | 116.95% | 14.75% | 15.02% | -415.92% |